NCT06022822 2026-03-18
Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
National Cancer Institute (NCI)
NRG Oncology
Ontario Clinical Oncology Group (OCOG)
Abramson Cancer Center at Penn Medicine
Alessa Therapeutics Inc.
Alessa Therapeutics Inc.
Hackensack Meridian Health
Mayo Clinic
NRG Oncology
Jonsson Comprehensive Cancer Center